INT230-6
Early-Stage Triple-Negative Breast Cancer (Neoadjuvant)
Key Facts
About Intensity Therapeutics
Intensity Therapeutics is pioneering a 'treat locally, act globally' approach to cancer therapy. Its core DfuseRx platform uses novel penetration enhancers to disperse cytotoxic drugs throughout injected tumors, inducing immunogenic cell death and triggering a CD4+/CD8+ T-cell response against both local and distant metastases. The company is advancing its lead asset, INT230-6, through multiple mid-to-late-stage trials in challenging solid tumors, with a strategic focus on neoadjuvant and metastatic settings to improve survival and prevent recurrence.
View full company profileAbout Intensity Therapeutics
Intensity Therapeutics is pioneering a 'treat locally, act globally' approach to cancer therapy. Its core DfuseRx platform uses novel penetration enhancers to disperse cytotoxic drugs throughout injected tumors, inducing immunogenic cell death and triggering a CD4+/CD8+ T-cell response against both local and distant metastases. The company is advancing its lead asset, INT230-6, through multiple mid-to-late-stage trials in challenging solid tumors, with a strategic focus on neoadjuvant and metastatic settings to improve survival and prevent recurrence.
View full company profileAbout Intensity Therapeutics
Intensity Therapeutics is pioneering a 'treat locally, act globally' approach to cancer therapy. Its core DfuseRx platform uses novel penetration enhancers to disperse cytotoxic drugs throughout injected tumors, inducing immunogenic cell death and triggering a CD4+/CD8+ T-cell response against both local and distant metastases. The company is advancing its lead asset, INT230-6, through multiple mid-to-late-stage trials in challenging solid tumors, with a strategic focus on neoadjuvant and metastatic settings to improve survival and prevent recurrence.
View full company profileAbout Intensity Therapeutics
Intensity Therapeutics is pioneering a 'treat locally, act globally' approach to cancer therapy. Its core DfuseRx platform uses novel penetration enhancers to disperse cytotoxic drugs throughout injected tumors, inducing immunogenic cell death and triggering a CD4+/CD8+ T-cell response against both local and distant metastases. The company is advancing its lead asset, INT230-6, through multiple mid-to-late-stage trials in challenging solid tumors, with a strategic focus on neoadjuvant and metastatic settings to improve survival and prevent recurrence.
View full company profile